CJC-1295 No DAC & Ipamorelin Half-Life — Dosing Timing

The biggest reconstitution mistake researchers make with CJC-1295 no DAC isn't the mixing ratio. It's expecting it to behave like its DAC-modified counterpart. CJC-1295 no DAC (also called Modified GRF 1-29) has a plasma half-life of approximately 30 minutes, while ipamorelin stays active for roughly 2 hours. That narrow window isn't a design flaw. It's the mechanism that makes this combination so effective at amplifying natural growth hormone pulses without suppressing endogenous production the way longer-acting analogues can.

We've worked with research teams across cellular metabolism and peptide stability studies for years. The gap between protocols that work and those that waste expensive compounds comes down to three things most mixing guides never mention: precise reconstitution timing, temperature-controlled storage post-mixing, and dosing intervals that respect physiological GH pulse architecture.

What's the half-life of CJC-1295 no DAC and ipamorelin?

CJC-1295 no DAC (Modified GRF 1-29) has a plasma half-life of approximately 30 minutes, meaning peak growth hormone release occurs within 15–20 minutes of administration and returns to baseline within 90–120 minutes. Ipamorelin has a half-life of roughly 2 hours, with measurable GH elevation sustained for 3–4 hours post-injection. These short durations allow for multiple daily dosing without desensitising somatotroph cells or suppressing endogenous pulsatile secretion.

Here's what the basic answer misses: those half-lives don't exist in isolation. They're designed to synergise. CJC-1295 no DAC amplifies the amplitude of each GH pulse (how high the spike goes), while ipamorelin extends pulse duration (how long it stays elevated). The combination mimics the body's natural overnight GH secretion pattern: sharp peaks followed by sustained elevation, then a clean return to baseline before the next pulse. This article covers exactly how those pharmacokinetics translate into dosing protocols, what reconstitution and storage timelines preserve peptide integrity, and what preparation errors negate bioavailability entirely.

How CJC-1295 No DAC & Ipamorelin Work Differently From DAC Variants

CJC-1295 no DAC is Modified GRF 1-29. A truncated 29-amino-acid analogue of growth hormone-releasing hormone (GHRH) that binds to GHRH receptors on anterior pituitary somatotrophs. Without drug affinity complex (DAC) modification, it remains unbound to serum albumin, allowing rapid clearance. Peak plasma concentration occurs at 15–20 minutes, half-life is 30 minutes, and measurable GH elevation returns to baseline within 90–120 minutes.

Ipamorelin is a ghrelin mimetic. It binds to ghrelin receptors (GHS-R1a) on the same somatotroph cells, triggering GH release through a pathway independent of GHRH. Its half-life is approximately 2 hours, with sustained GH elevation lasting 3–4 hours before clearance. Because it doesn't stimulate ACTH or cortisol release (unlike GHRP-2 or GHRP-6), it produces clean GH pulses without adrenal activation.

The DAC-modified version of CJC-1295 (often mislabelled as 'CJC-1295 with DAC') has a half-life of 6–8 days due to albumin binding, creating chronically elevated GH levels rather than pulsatile secretion. Research in endocrinology models shows that sustained GH elevation without normal troughs can lead to receptor desensitisation, blunted response over time, and suppression of natural pulsatile secretion. Modified GRF 1-29 avoids this by respecting the body's circadian GH architecture. Sharp pulses during deep sleep and post-exercise recovery, followed by baseline periods that preserve receptor sensitivity.

Reconstitution & Storage Timelines That Preserve Peptide Integrity

Lyophilised CJC-1295 no DAC and ipamorelin must be stored at −20°C before reconstitution. Once mixed with bacteriostatic water (0.9% benzyl alcohol), both peptides are stable at 2–8°C for 28 days. Temperature excursions above 8°C. Even for 30–60 minutes during shipping or handling. Cause irreversible conformational changes to the peptide backbone. Neither visual inspection nor at-home potency testing can detect this denaturation.

Reconstitution protocol: inject bacteriostatic water slowly along the inside wall of the vial, allowing it to run down the glass rather than spraying directly onto the lyophilised cake. The peptide will dissolve passively within 60–90 seconds without agitation. Shaking or vigorous swirling shears peptide bonds, reducing bioavailability by 15–40% based on stability studies of similar modified GHRH analogues.

Post-reconstitution storage requires consistent refrigeration. Every freeze-thaw cycle reduces potency by approximately 10–20%. If travelling, purpose-built peptide coolers (like FRIO insulin wallets) maintain 2–8°C for 36–48 hours using evaporative cooling without electricity. Standard ice packs risk freezing reconstituted peptides, which denatures them just as effectively as heat exposure.

Our Real Peptides team ships lyophilised peptides with temperature-logging cold packs and includes reconstitution instructions with every vial. We've found that most degradation happens during the 72-hour window between mixing and first use. Not during long-term storage.

Dosing Windows & Stacking Protocols for Synergistic GH Pulses

Optimal dosing for CJC-1295 no DAC ranges from 100–200 mcg per injection, administered 1–3 times daily. Ipamorelin is dosed at 200–300 mcg per injection, matched to the same frequency. The two are almost always co-administered in the same syringe to maximise synergy: CJC amplifies pulse amplitude, ipamorelin extends duration.

Timing matters more than dosage volume. GH pulses naturally occur during deep sleep (stages 3–4 NREM) and immediately post-exercise. Administering the stack 30–60 minutes before sleep aligns with endogenous nocturnal secretion, compounding the effect. A second dose can be administered upon waking or immediately post-training to amplify exercise-induced GH release.

Critical spacing rule: doses should be separated by at least 4–6 hours. Administering a second injection before the first pulse resolves (within 3 hours) creates overlapping GH elevation without additional amplitude. Essentially wasting the second dose. The body's somatotroph cells require a refractory period to replenish releasable GH stores.

Researchers often pair CJC-1295 no DAC and ipamorelin with compounds like GHRP 2 or MK 677 in metabolic research models. MK-677 (ibutamoren) is an oral ghrelin mimetic with a 24-hour half-life. It maintains baseline GH elevation between injected pulses, creating a hybrid protocol that combines pulsatile peaks with sustained trough support.

CJC-1295 No DAC & Ipamorelin: Peptide Comparison

Key Takeaways

• CJC-1295 no DAC has a 30-minute half-life with peak GH release at 15–20 minutes, designed to amplify natural pulse amplitude without sustained elevation.
• Ipamorelin has a 2-hour half-life and extends GH elevation for 3–4 hours, creating synergy when co-administered with CJC-1295 no DAC.
• Lyophilised peptides must be stored at −20°C before reconstitution; once mixed with bacteriostatic water, refrigerate at 2–8°C and use within 28 days.
• Temperature excursions above 8°C cause irreversible peptide denaturation that neither appearance nor potency testing at home can detect.
• Optimal dosing is 1–3 times daily, spaced at least 4–6 hours apart to respect the body's GH pulse refractory period.
• Co-administration 30–60 minutes before sleep or immediately post-training aligns with endogenous GH secretion patterns for maximum synergy.

What If: CJC-1295 No DAC & Ipamorelin Scenarios

What If I Accidentally Left Reconstituted Peptides Out of the Fridge Overnight?

Discard the vial. Reconstituted peptides exposed to temperatures above 8°C for more than 2–3 hours undergo irreversible conformational changes to the peptide backbone. The solution may still appear clear, but bioavailability is compromised. Injecting denatured peptide wastes the dose and skews research data. Lyophilised (unmixed) peptides can tolerate brief ambient exposure (24–48 hours at 20–25°C), but once reconstituted, cold chain integrity is non-negotiable.

What If I Mix CJC-1295 No DAC and Ipamorelin in the Same Syringe?

This is standard practice and actively recommended. Both peptides are reconstituted in bacteriostatic water at neutral pH, making them chemically compatible when drawn into the same syringe. Co-administration ensures simultaneous GHRH receptor and ghrelin receptor activation, maximising synergistic GH release. Draw ipamorelin first (higher volume), then CJC-1295 no DAC. Total injection volume typically ranges from 0.3–0.5 mL subcutaneously.

What If I Want to Dose Only Once Daily Instead of Multiple Times?

Single daily dosing is viable but suboptimal for replicating natural pulsatile GH secretion. Administering the stack 30–60 minutes before sleep captures the body's primary nocturnal GH pulse, which accounts for 60–70% of daily GH output. A second morning or post-training dose amplifies exercise-induced pulses, compounding metabolic and recovery effects. Research models using single daily dosing show measurable results, but twice-daily protocols consistently demonstrate greater IGF-1 elevation and fat oxidation markers.

What If the Lyophilised Powder Looks Clumped or Discoloured Before Reconstitution?

Lyophilised peptides should appear as a uniform white or off-white cake. Discolouration (yellow, brown, or grey tint) or excessive clumping suggests oxidative degradation, likely from improper storage or manufacturing contamination. Do not reconstitute. Contact the supplier for replacement. High-purity peptides from regulated 503B facilities like those offered by Real Peptides undergo third-party purity verification (≥98% via HPLC) and include certificates of analysis with every batch.

The Clinical Truth About CJC-1295 No DAC Half-Life Expectations

Here's the honest answer: researchers new to peptide protocols often assume longer half-lives equate to better efficacy. That's backwards for growth hormone secretagogues. The 30-minute half-life of CJC-1295 no DAC and the 2-hour duration of ipamorelin aren't limitations. They're the mechanism that preserves physiological GH architecture.

Chronic GH elevation from long-acting analogues (like DAC-modified CJC or synthetic GH itself) suppresses the body's natural pulsatile secretion over time. Somatotroph cells downregulate GHRH and ghrelin receptors when constantly stimulated, blunting response and reducing endogenous GH production. Modified GRF 1-29 avoids this by creating sharp, transient pulses followed by clean baseline periods. Exactly how the body regulates GH during deep sleep and recovery.

The short half-life also reduces off-target effects. Sustained GH elevation increases IGF-1 chronically, which research links to insulin resistance, joint oedema, and carpal tunnel symptoms in long-term models. Pulsatile protocols using CJC-1295 no DAC and ipamorelin elevate IGF-1 within physiological ranges (200–300 ng/mL in human equivalent studies) without the supraphysiological spikes that cause these adverse events.

Most peptide protocols fail not at the injection stage but during the reconstitution and storage window. A single temperature excursion during shipping, a freeze-thaw cycle, or agitation during mixing denatures the peptide irreversibly. Visual clarity means nothing. Denatured peptides remain transparent but lose biological activity entirely.

The most common mistake we see is dosing CJC-1295 no DAC once weekly because researchers confuse it with the DAC variant. Modified GRF 1-29 requires multiple daily doses to sustain pulsatile GH secretion. Weekly dosing wastes the compound. By the time you inject again, seven days of potential pulses have passed with zero GH amplification. If your protocol involves weekly injections, you're using the wrong peptide.

For researchers exploring synergistic approaches, pairing CJC-1295 no DAC and ipamorelin with metabolic support compounds can enhance measurable outcomes. Our FAT Loss Stack and Body Recomp Bundle combine peptides with complementary mechanisms. GH secretagogues paired with mitochondrial activators and insulin sensitisers. To model the full cascade of metabolic effects rather than isolating GH alone.

CJC-1295 no DAC's 30-minute half-life isn't a weakness. It's proof the peptide was designed to work with the body's endocrine system, not override it. Respect the pharmacokinetics, and the results follow. Ignore them, and you're running an expensive saline protocol.